5 withdrawn. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Withdrawn 5 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma Ixazomib, Pomalidomide, Lenalidomide - Multiple Myeloma | Phase 4 | Withdrawn | Takeda | 2022-06-30 | 2022-05-03 | |
| Reinforcement Learning for Warfarin Dosing Reinforcement Learning, Heath Care Provider - Clotting Disorder | Phase 4 | Withdrawn | University of Louisville | 2022-01-01 | 2022-03-04 | |
| Study Using Plasma for Patients Requiring Emergency Surgery Human Plasma - Hemorrhagic Shock, Blood Coagulation Disorders | Phase 4 | Withdrawn | Ottawa Hospital Research Institute | 2012-03-01 | 2023-05-08 | |
| Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Kyphoplasty/Vertebral Augmentation (Device-StabiliT) - Multiple Myeloma, Compression Fracture of Vertebral Column | Phase 4 | Withdrawn | DFINE Inc. | 2011-05-01 | 2017-01-20 | |
| Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Zoledronic acid - Multiple Myeloma | Phase 4 | Withdrawn | Novartis | 2004-04-01 | 2015-04-14 |
Multiple Myeloma (3) · Back Pain (1) · Blood Coagulation Disorders (1) · Hemorrhage (1) · Neoplasms (1) · Shock, Hemorrhagic (1) · Wounds and Injuries (1)
Cardiovascular Diseases (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Hemorrhagic Disorders (5) · Vascular Diseases (5) · Blood Protein Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3) · Neoplasms (2) · Pathological Conditions, Signs and Symptoms (2)
Dexamethasone (1) · Kyphoplasty (1) · Lenalidomide (1) · Reinforcement Machine Learning (1) · Zoledronic Acid (1) · ixazomib (1) · pomalidomide (1)
DFINE Inc. (1) · Novartis (1) · Ottawa Hospital Research Institute (1) · Takeda (1) · University of Louisville (1)
Canada (1)
David T Neilipovitz, MD (1) · Frank Vrionis, MD, MPH, PhD (1)